Given the still dismal overall prognosis for cancer patients, the need is evident to improve the efficacy of novel targeted and personalized anticancer therapies. A therapeutic plateau has been reached with conventional anticancer strategies. More recently, numerous molecular targets and effective homing molecules were discovered. However, this process is highlighting even more new potent compounds to test for possible utility in the battle against cancer.
KINETO Lab Ltd. is specialized in development and use of preclinical models for testing various anticancer strategies and treatments. We have substantial experience in designing experiments, and performing in vitro screening and in vivo studies. Our models can be originated from human (xenograft) or murine (allograft) tumor cell lines. Additionally, we also have established a variety of patient-derived tumor xenografts (PDTXs).
KINETO Lab Ltd. has all official and ethical licenses and expertised staff to conduct animal experiments.
KINETO Lab’s mission is to establish scientifically founded strategies and provide high quality services to our partners’ in vitro and in vivo development and testing of anticancer technologies and treatments, enhancing quality of drug discovery.